



Estd : 2005

Sri Indu Institute of Pharmacy

UGC Autonomous Institution, Accredited by NAAC (Grade "A")

Recognized Under Section 2(f) of UGC Act 1956.

Approved by PCI- New Delhi, Affiliated to JNTUH- Hyderabad.

Sheriguda (V), Ibrahimpatnam (M), R.R. Dist-501510.

Phone: + 91-9391537555 Website: www.slip.ac.in Email:slipoffice@slip.ac.in

MEMORANDUM OF UNDERSTANDING

Academic Collaboration • Skill Development • Career Guidance • Workshops • Internship-Oriented Learning • Professional Development

BETWEEN

SRI INDU INSTITUTE OF PHARMACY

AND

MEDCLINIGEN (OPC) PRIVATE LIMITED

SRI INDU INSTITUTE OF PHARMACY Autonomous Institution under UGC NAAC Accredited Approved by Pharmacy Council of India (PCI), New Delhi Affiliated to Jawaharlal Nehru Technological University Hyderabad (JNTUH)	MEDCLINIGEN (OPC) PRIVATE LIMITED Incorporated under the Companies Act, 2013 Registered with the Ministry of Corporate Affairs, Government of India MSME Udyam Registered ISO 9001:2015 & ISO 21001:2018
--	--

TERM: TEN (10) YEARS FROM THE DATE OF EXECUTION

Execution Date: 01.Place: _____

1. PARTIES

SRI INDU INSTITUTE OF PHARMACY, an Autonomous Institution under UGC, NAAC Accredited, approved by the Pharmacy Council of India (PCI), New Delhi, and affiliated to Jawaharlal Nehru Technological University Hyderabad (JNTUH), located at Sheriguda Village, Ibrahimpatnam, Ranga Reddy District, Telangana – 501510, represented by **Dr. P. Vishnu Priya, Principal & Professor, Authorised Signatory** (hereinafter referred to as the "Institution");

AND

MEDCLINIGEN (OPC) PRIVATE LIMITED, a company incorporated under the Companies Act, 2013 and registered with the Ministry of Corporate Affairs, Government of India, having CIN U85499TS2026OPC216021, Telangana, India, and identified as MSME Udyam Registered and ISO 9001:2015 & ISO 21001:2018, represented by **Dr. Rahul Gopal, Director, Founder & CEO, Authorised Signatory** (hereinafter referred to as "MEDCLINIGEN").

The Institution and MEDCLINIGEN are individually referred to as a "Party" and collectively as the "Parties."

2. BACKGROUND AND PURPOSE

The Institution proposes to collaborate with MEDCLINIGEN to strengthen academic enrichment, student employability, professional readiness and industry-oriented awareness in healthcare, pharmaceutical, clinical research and allied life-sciences domains.

The collaboration may include mutually approved workshops, seminars, webinars, guest lectures, career-guidance sessions, domain-awareness programmes, internship-oriented learning, faculty-student interactions, educational assessments and professional-development activities.

3. OBJECTIVES

- Provide students with structured exposure to emerging career opportunities in Clinical Research, Pharmacovigilance, Clinical Data Management, Regulatory Affairs, Medical Writing, healthcare and allied domains.
- Enhance employability through resume development, LinkedIn optimisation, professional email writing, interview preparation, communication skills and career mentorship.
- Facilitate industry-relevant learning, professional communication, ethical practices and responsible use of digital and AI tools.
- Promote meaningful academic-industry interaction through transparent, ethical and student-centric activities.



4. SCOPE OF COLLABORATION

- Career-awareness and domain-orientation sessions for B.Pharm, M.Pharm and Pharm.D students.
- Skill-development workshops covering ATS-compatible resumes, LinkedIn optimisation, professional email writing, interview readiness, career-portal navigation, presentation skills, AI-tools awareness and professional branding.
- Academic sessions in Clinical Research, ICH-GCP, Pharmacovigilance, Drug Safety, Clinical Data Management, Regulatory Affairs, Medical Writing and Drug Development.
- Guest lectures, webinars, seminars, workshops, mock tests, educational quizzes and certificate-based learning activities.
- Internship-oriented, project-based and practical case-based professional development, where separately approved.

5. PROGRAMME APPROVAL AND IMPLEMENTATION

Each specific activity shall be confirmed through a written proposal, official email approval, work order or separate agreement setting out the relevant objectives, dates, mode of delivery, participants, responsibilities, deliverables, financial terms, certification criteria, branding requirements and data requirements.

Neither Party shall make employment, placement, admission, certification, academic-credit or financial commitments on behalf of the other Party without prior written authorisation.

6. RESPONSIBILITIES OF THE INSTITUTION

- Nominate authorised faculty/student coordinators and facilitate communication with relevant departments.
- Provide reasonable institutional support and suitable arrangements for approved activities, subject to availability.
- Communicate approved programme information accurately to eligible students and faculty.
- Share only necessary participant information for approved purposes and maintain appropriate student discipline.
- Ensure MEDCLINIGEN's name, logo and materials are used only as approved.
- Prevent unauthorised fee collection, representation or certification on behalf of MEDCLINIGEN.
- Support feedback and academic evaluation of mutually approved activities.

7. RESPONSIBILITIES OF MEDCLINIGEN

- Deliver mutually approved academic, professional and career-development activities.
- Provide appropriate educational resources, trainers and professional guidance.
- Coordinate with the Institution for programme planning and implementation.
- Issue certificates only to participants who satisfy approved eligibility criteria.
- Maintain professional, ethical and student-centric standards.
- Protect confidential information and personal data.
- Use transparent and non-misleading representations concerning programmes, outcomes and professional opportunities.

8. FINANCIAL TERMS

This MoU creates **no automatic financial obligation or minimum business commitment**. Any paid workshop, training, certification, internship-oriented programme, sponsorship, honorarium, revenue-sharing arrangement or other commercial activity shall be governed by a separate written agreement or approved proposal.

Neither Party may collect fees, issue receipts, offer discounts or create payment/refund obligations on behalf of the other without written authorisation.

9. BRANDING, PUBLICITY AND REPRESENTATION

Neither Party shall use the other's name, logo, accreditation, affiliation or institutional identity except for mutually approved purposes. Posters, certificates, photographs, videos, social-media content, press releases and public communications relating to the collaboration require prior approval.

This MoU shall not be represented as creating a university affiliation, franchise, statutory recognition, placement partnership, employment guarantee, academic-credit arrangement or exclusive relationship.

10. CERTIFICATION AND STUDENT OUTCOMES

Certificates may be issued individually or jointly, subject to prior written approval. Certificate title, wording, design, logos, signatories and eligibility criteria shall be approved before issuance.

Certificates shall not be represented as degrees, statutory licences, academic credits, government approvals, professional licences or regulatory certifications unless independently authorised by the competent authority.

Participation does not guarantee employment, placement, salary, internship selection, admission, academic credit, professional licensing or government certification. Recruitment decisions remain exclusively with the relevant employer or organisation.

11. CONFIDENTIALITY AND PERSONAL DATA PROTECTION

Each Party shall keep confidential all non-public institutional, student, commercial and educational information received from the other Party.

Personal data shall be collected and processed only for specified, lawful and approved purposes and only to the extent reasonably necessary. Neither Party shall sell, misuse, publish, transfer or disclose such information for unauthorised use.

The Parties shall implement reasonable safeguards and comply with applicable data-protection law. Confidentiality and data-protection obligations shall survive expiry or termination.

12. INTELLECTUAL PROPERTY AND RECORDING RESTRICTIONS

Each Party shall retain ownership of its pre-existing intellectual property, including content, presentations, training materials, templates, videos, designs, logos, methodologies, educational resources and confidential know-how.

MEDCLINIGEN shall retain ownership of its training modules, course content, study materials, presentations, certificate formats and designs, templates, videos, brand assets and programme methodologies.

No material may be copied, recorded, reproduced, distributed or commercially exploited without prior written permission, except where expressly authorised in writing.

13. COMPLIANCE AND ETHICAL CONDUCT

Both Parties shall comply with applicable laws, institutional policies, professional ethics and academic standards and shall maintain transparent, respectful and non-misleading communication.

14. LIABILITY AND INDEMNITY

Each Party shall be responsible for its own acts, omissions and authorised representatives. Each Party shall indemnify the other against third-party claims arising from its material breach, negligence, fraud, wilful misconduct, unauthorised representation, data misuse, intellectual-property infringement or violation of applicable law, subject to this MoU.

15. NON-EXCLUSIVITY

This MoU is non-exclusive. Each Party remains free to collaborate with other organisations. Nothing herein creates a partnership, joint venture, agency, franchise, employment relationship, university affiliation or authority for one Party to legally bind the other.

16. TERM AND TERMINATION

This MoU shall remain valid for **five (5) years from the date of execution**, unless terminated earlier in accordance with this clause.

Either Party may terminate this MoU by providing **30 days' written notice**. Immediate termination or suspension may occur in cases of serious misconduct, unauthorised fee collection, misuse of name or logo, false representation, confidentiality or data breach, intellectual-property infringement, unlawful conduct or other material breach.

Termination shall not affect completed activities, accrued obligations or provisions intended to survive, including confidentiality, data protection, intellectual property, indemnity, liability, dispute resolution and governing law.

17. FORCE MAJEURE

Neither Party shall be liable for delay or failure caused by circumstances beyond reasonable control, including natural disasters, epidemics or pandemics, government restrictions, institutional closure, internet or utility failure, civil disturbance or similar events. The Parties shall cooperate in good faith regarding rescheduling, alternate delivery or cancellation.

18. DISPUTE RESOLUTION, GOVERNING LAW AND JURISDICTION

The Parties shall first attempt to resolve any dispute through good-faith discussions between authorized representatives.

If unresolved, the dispute shall be referred to a sole arbitrator mutually appointed by the Parties in accordance with the **Arbitration and Conciliation Act, 1996, as amended**. If the Parties cannot mutually appoint the arbitrator, appointment shall be made in accordance with the Act.

The **seat and venue of arbitration shall be Hyderabad, Telangana**. Proceedings shall be conducted in English. This MoU shall be governed by the laws of India. Courts of competent jurisdiction at Hyderabad, Telangana shall have jurisdiction for interim measures, enforcement and matters not capable of arbitration, to the extent legally permissible.

19. NOTICES

Official notices shall be delivered by hand, registered post, recognised courier or email to the addresses officially notified by the Parties. Each Party shall promptly notify the other of any change in its official address, email or authorised representative.

INSTITUTION: Dr. P. Vishnu Priya, Principal & Professor, Sri Indu Institute of Pharmacy; Sheriguda Village, Ibrahimpatnam, Ranga Reddy District, Telangana – 501510; official institutional contact details as notified in writing.

MEDCLINIGEN: Dr. Rahul Gopal, Director, Founder and CEO; Email: medclinigenacademy@gmail.com; Contact: +91 9182190048; registered office/correspondence address as officially notified in writing.

20. AMENDMENTS, SEVERABILITY AND ENTIRE UNDERSTANDING

Any amendment or modification shall be valid only when made in writing and approved by authorised representatives of both Parties.

If any provision is held invalid or unenforceable, it shall be modified to the minimum extent necessary and the remaining provisions shall continue in effect.

This MoU, together with duly approved proposals, work orders, written activity approvals and separate agreements, constitutes the complete understanding between the Parties concerning its subject matter.

21. NATURE AND BINDING EFFECT

This MoU establishes a framework for academic and professional collaboration and does not obligate either Party to conduct a minimum number of activities, enrol students, incur expenditure or enter into any specific commercial programme unless separately approved in writing.

The provisions concerning approved financial obligations, confidentiality, data protection, intellectual property, branding, certification integrity, indemnity, liability, dispute resolution and governing law shall remain binding as applicable.

DECLARATION AND EXECUTION

The Parties declare that they have read, understood and agreed to the terms of this MoU. The undersigned representatives confirm that they are duly authorised to execute this document on behalf of their respective organisations.

FOR SRI INDU INSTITUTE OF PHARMACY	FOR MEDCLINIGEN (OPC) PRIVATE LIMITED
Dr. P. Vishnu Priya Principal & Professor Authorised Signatory Signature: <u>[Signature]</u> Seal: _____ Date & Place: _____ PRINCIPAL SRI INDU INSTITUTE OF PHARMACY	Dr. Rahul Gopal Director, Founder & CEO Authorised Signatory CIN: U85499TS2026OPC216021 Signature: <u>[Signature]</u> Seal: _____ Date & Place: <u>21/9/2026, Sheriguda</u>

Sheriguda (V), Ibrahimpatnam (M),
R.R. Dist. Hyderabad-501 510

WITNESSES

WITNESS 1	WITNESS 2
Name: Dr. P. SWATHI Designation / Organization: ASSOCIATE PROFESSOR SRI INDU INSTITUTE OF PHARMACY Signature: <u>[Signature]</u> Contact: <u>9701424614.</u>	Name: Dr JAFFER SADIK MOHAMMED Designation: ASSOCIATE PROFESSOR SRI INDU INSTITUTE OF PHARMACY Signature: <u>[Signature]</u> Contact: <u>8686992959</u>




TERM: FIVE (5) YEARS FROM THE DATE OF EXECUTION

SRI INDU INSTITUTE OF PHARMACY — Autonomous Institution under UGC | NAAC Accredited | PCI Approved | Affiliated to JNTUH

MEDCLINIGEN (OPC) PRIVATE LIMITED — Companies Act, 2013 | Ministry of Corporate Affairs, Government of India | MSME Udyam Registered | ISO 9001:2015 & ISO 21001:2018

SRI INDU INSTITUTE OF PHARMACY

ORGANIZATIONAL CHART



COURSE
B.Pharm
M.Pharm
EXAMINATION
I.Y
II.Y
III.Y
M.Pharm - Phase-I

GPS video camera

SRI INDU INSTITUTE OF PHARMACY 🇮🇳

Telangana-501510, INDIA, SRI INDU INSTITUTE OF
PHARMACY, 500088,

Lat 17.21015° Long 78.610334°

Wednesday, 02/09/2026 02:58:06 PM GMT +05:30





Wednesday, 02/09/2026 02:58:55 PM GMT +05:30

